Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | PPARA | Q07869 | 7/20 | 0.53 |
| ▸ | PPARG | P37231 | 4/20 | 0.53 |
| ▸ | PPARD | Q03181 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247466 | 0.77 | PPARA (0.68) | KMT2APPARAPPARGPPARDMEN1 | |
| SCHEMBL29168850 | 0.76 | KMT2A (0.57) | SCN2ACA9CA12CA1CA2 | |
| SCHEMBL30758589 | 0.76 | KMT2A (0.57) | SCN2ACA9CA12CA1CA2 | |
| SCHEMBL7150732 | 0.75 | GLA (0.61) | SCN2ACA9CA12CA1CA2 | |
| Ammonia Solution, Strong SCHEMBL7026339 | 0.75 | PPARA (0.66) | KMT2APPARAPPARGPPARDMEN1 | |
| SCHEMBL7032523 | 0.75 | PPARA (0.66) | KMT2APPARAPPARGPPARDMEN1 | |
| Hydrochloric Acid SCHEMBL8889149 | 0.75 | PPARA (0.66) | KMT2APPARAPPARGPPARDMEN1 | |
| SCHEMBL2550387 | 0.74 | NR1H3 (0.81) | SCN2AKMT2AMEN1MAPTNR1H3 | |
| SCHEMBL13302880 | 0.74 | MGLL (0.65) | SCN2ACA9CA12CA1CA2 | |
| SCHEMBL9416379 | 0.74 | PPARA (0.65) | KMT2APPARAPPARGPPARDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176445-A1 | Propionic acid derivatives | BAYER PHARMACEUTICALS CORPORATION | 2004-09-09 | — | — | US | disclosed |
| US-6750236-B2 | CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-15 | — | — | US | disclosed |
| US-20030187041-A1 | Propionic acid derivatives | URBAHNS KLAUS (DE) | 2003-10-02 | — | — | US | disclosed |
| US-6548538-B2 | Potent peroxisome proliferator activated receptor (PPAR)-alpha-activating compounds; propionic acid 2-subsituted with an N-(phenylaminocarbonylalkyl), N-(2-furanylmethyl)aminoalkylphenyl group | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-15 | — | — | US | disclosed |
| US-20030032671-A1 | Propionic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187041-A1 | Propionic acid derivatives | PPARA, PPARD, PPARG | SCN2A 1924/4885CA9 3287/4885CA12 4176/4885 |
| US-20030032671-A1 | Propionic acid derivatives | PPARD, PPARA, PPARG | SCN2A 1518/4885CA9 3839/4885CA12 4472/4885 |
| US-20040176445-A1 | Propionic acid derivatives | PPARD, PPARA, PPARG | SCN2A 1518/4885CA9 3839/4885CA12 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.